Tysabri is top DMT in new studyPublished: 14 July 2023 A new clinical trial which compared six disease-modifying therapies (DMTs) found that Tysabri (natalizumab) was better than the five others at reducing relapses and stopping disability worsening in people with multiple sclerosis (MS). This was a novel simulated clinical trial in which researchers used a mathematical model to incorporate data from over 20,000 people in a global MS registry. The second best DMT for improving outcomes was found to be Gilenya (fingolimod). Overall, Tysabri, ahead of Gilenya, is most effective in preventing relapses, disability worsening and enabling disability improvement in relapsing-remitting MS,” the researchers wrote. “However,” the team noted, “the individual use of these therapies should be also guided by specific clinical scenarios and their safety profiles, which were not evaluated in this study.” Other Stories You May Be Interested In... News Number of people living with MS in UK increases View article News Study finds MS may marginally increase cervical cancer risk View article News Antibodies detected in blood of 10% of MS patients years before diagnosis View article